company background image
SH0 logo

Shionogi DB:SH0 Stock Report

Last Price

€46.60

Market Cap

€13.4b

7D

-0.9%

1Y

11.0%

Updated

26 Mar, 2024

Data

Company Financials +

SH0 Stock Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

SH0 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends5/6

Shionogi & Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shionogi
Historical stock prices
Current Share PriceJP¥46.60
52 Week HighJP¥48.60
52 Week LowJP¥36.60
Beta0.36
1 Month Change6.39%
3 Month Change9.91%
1 Year Change10.95%
3 Year Change1.75%
5 Year Change-13.54%
Change since IPO241.64%

Recent News & Updates

Recent updates

Shareholder Returns

SH0DE PharmaceuticalsDE Market
7D-0.9%2.3%1.9%
1Y11.0%-25.9%7.3%

Return vs Industry: SH0 exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.

Return vs Market: SH0 exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is SH0's price volatile compared to industry and market?
SH0 volatility
SH0 Average Weekly Movement3.0%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: SH0 has not had significant price volatility in the past 3 months.

Volatility Over Time: SH0's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18785,680Isao Teshirogihttps://www.shionogi.com

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.

Shionogi & Co., Ltd. Fundamentals Summary

How do Shionogi's earnings and revenue compare to its market cap?
SH0 fundamental statistics
Market cap€13.44b
Earnings (TTM)€940.82m
Revenue (TTM)€2.59b

14.3x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SH0 income statement (TTM)
RevenueJP¥425.16b
Cost of RevenueJP¥60.08b
Gross ProfitJP¥365.08b
Other ExpensesJP¥210.62b
EarningsJP¥154.46b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 13, 2024

Earnings per share (EPS)542.78
Gross Margin85.87%
Net Profit Margin36.33%
Debt/Equity Ratio0%

How did SH0 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

28%

Payout Ratio

Does SH0 pay a reliable dividends?

See SH0 dividend history and benchmarks
When do you need to buy SH0 by to receive an upcoming dividend?
Shionogi dividend dates
Ex Dividend DateMar 28 2024
Dividend Pay DateJun 24 2024
Days until Ex dividend1 day
Days until Dividend pay date89 days

Does SH0 pay a reliable dividends?

See SH0 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.